Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis

Discussion In this large propensity score-matched cohort of patients with heart failure, dual therapy with SGLT2 inhibitors and GLP-1 analogues was not associated with significant differences in all-cause mortality, acute myocardial infarction, acute kidney failure, atrial fibrillation/flutter, all-cause hospitalization, or new-onset diuretic use compared with SGLT2 inhibitor monotherapy over 365 days of follow-up, while pulmonary edema and hypoglycemia showed borderline significant increases.

also in 11,409 other papers

Hypoglycemia and pulmonary edema retained borderline significance under BH-FDR adjustment (q = 0.05) but did not remain significant following Bonferroni correction.

also in 7,017 other papers